Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$342.59 USD

342.59
288,134

-2.43 (-0.70%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $342.56 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?

Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?

MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.

Is First Trust Mid Cap Value AlphaDEX ETF (FNK) a Strong ETF Right Now?

Smart Beta ETF report for FNK

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?

Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

UTHR or ZTS: Which Is the Better Value Stock Right Now?

UTHR vs. ZTS: Which Stock Is the Better Value Option?

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat

Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines.

Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.

3 Reasons Why Growth Investors Shouldn't Overlook United Therapeutics (UTHR)

United Therapeutics (UTHR) could produce exceptional returns because of its solid growth attributes.

Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates

Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. Stock rises.

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.

Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

United Therapeutics (UTHR) Misses Q2 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -7.58% and 4.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?

Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.